Abstract:4600 Background: Hepatocellular carcinoma (HCC) represents the second most common cause of cancer deaths worldwide. □-fetoprotein (AFP) is the most common serological test used for screening and diagnosis of HCC. However, it is widely recognized that AFP has lower sensitivity with sub-optimal specificity. Tumor-originated circulating cell-free DNA (cfDNA) provides new opportunity for non-invasive detection of liver cancer. Methods: HCC-specific differentially methylated regions (DMRs) were identified by whole genome bisulfite sequencing (WGBS) in 44 pairs of HCC tissues and adjacent tissues. We then performed methylome profiling on cfDNA from HCC patients and healthy individuals by targeted bisulfite sequencing covering genome-wide CpG islands, shelves, and shores. We employed machine learning approaches to build diagnostic models based on cfDNA regional methylation level to classify the plasma of HCC (n = 140) from that of healthy individuals (n = 84). Further analyses were performed in the validation cohort, including 155 HCC patients, and a control group with 96 healthy individuals, 21 chronic hepatitis B infection (CHB)/liver cirrhosis (LC) patients and 34 patients with benign hepatic lesions (BHL). Area under the receiver operating characteristic curve (AUC-ROC) was used to evaluate diagnostic performance. Results: A random forest classifier achieved an AUC of 0.97 (sensitivity: 92.9%; specificity: 89.4%) with 10-fold cross-validation using a panel of 39 DMR markers. The AUC of the diagnostic panel was 0.93 (sensitivity: 81.3%; specificity: 90.7%) in validation cohort, and it performed equally well in detecting BCLC stage 0+A (AUC = 0.90; sensitivity: 74.7%) and AFP negative (AUC = 0.92; sensitivity: 79.4%) HCC, as well as differentiating HCC from CHB/LC and BHL. Based on these results, we have further developed a small targeted bisulfite sequencing panel covering 127 CpG sites for non-invasive diagnosis of HCC. The panel had similar performance in training and validation cohorts, an AUC of 0.96 (sensitivity: 90.7%, specificity: 88.2%) in the training set, and 0.91 (sensitivity: 80.0%, specificity: 88.7%) in the validation set. Conclusions: Our diagnostic panel with 39 DMR markers showed high sensitivity and specificity in HCC diagnosis as well as surveillance in high-risk populations for developing HCC. More importantly, simple diagnostic model show similar diagnostic performance for early HCC diagnosis, which was easily to transfer to clinical application in the future.

Electrochemical Identification of Hepatocellular Carcinoma Based on the Assay of Human Cervical Cancer Oncoprotein-1 in Serum

Hepatocellular Carcinoma Detection by Cell Sensor Based on Anti-GPC3 Single-Chain Variable Fragment

Emerging Biomolecules for Practical Theranostics of Liver Hepatocellular Carcinoma.

An Integrated Electrochemical POCT Platform for Ultrasensitive Circrna Detection Towards Hepatocellular Carcinoma Diagnosis.

Au Nanoflowers Modified Magnetic and Flexible Biosensor for Bisulfite-Free HCC Global DNA Methylation Detection

A PCR-free Screen-Printed Magnetic Electrode for the Detection of Circular RNA from Hepatocellular Cancer Based on a Back-Splice Junction

Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray.

An integrated microfluidic cytosensor coupled with self-calibration electrochemical/colorimetric dual-signal output for sensitive and accurate detection of hepatoma cells

Detection of circulating tumor cells in hepatocellular carcinoma using antibodies against asialoglycoprotein receptor, carbamoyl phosphate synthetase 1 and pan-cytokeratin

A new label free spiral sensor using impedance spectroscopy to characterize hepatocellular carcinoma in tissue and serum samples

Noninvasive Detection of Hepatocellular Carcinoma with Circulating Tumor DNA Features and Α-Fetoprotein

A magnetic SERS immunosensor for highly sensitive and selective detection of human carboxylesterase 1 in human serum samples

A Large‐scale, Multicenter Serum Metabolite Biomarker Identification Study for the Early Detection of Hepatocellular Carcinoma

Electrochemical Detection and Distribution Analysis of Β-Catenin for the Evaluation of Invasion and Metastasis in Hepatocellular Carcinoma.

HCC EV ECG Score: An Extracellular Vesicle‐based Protein Assay for Detection of Early‐Stage Hepatocellular Carcinoma

Serum and Urine Metabolite Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma*

Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method

Genome-wide Plasma Cell-Free DNA Methylation Profiling to Identify High-Performing Biomarkers for Early Detection of Hepatocellular Carcinoma.

Identification of a novel plasma metabolite panel as diagnostic biomarker for hepatocellular carcinoma

Identification of CCL20 and LCN2 as Efficient Serological Tools for Detection of Hepatocellular Carcinoma

Single cell glycan-linkages profiling for hepatocellular carcinoma early diagnosis using lanthanide encoded bacteriophage MS2 based ICP-MS